History of DIL Ltd.

YEAR EVENTS 1951 - The Comp. was Incorporated on 1st May, as a private limited Comp. under the name International Franchise Pvt. The Company manufacture drugs & pharmaceuticals, chemicals, cosmetics and toileteries. It started its activities with the manufacture of a brand of tooth paste & antiseptic lotion & extended them to the manufacture of pharmaceutical specialities of foreign companies on leave licence scheme.

- DIL was promoted by Solvay Pharmaceuticals based Brussels and Mr. D. Vasant Kumar & family in India.

1962 - The Collaboration agreements were concluded with N.V. Philips - Duphar of Amsterdam & the Crookes Laboratories Ltd., London. The Comp. became a public limited Comp. with effect from 9th April, 1963 & simultaneously its name was changed to Crookes Interfran Ltd.

- The Comp. was entitled to obtain technical know-how for the manufacture of basic chemical, Vitamin `D' from N.V. Philips `Gloeilampenfabrieken, Holland.

1967 - The first phase of vitamin `D' manufacture was undertaken in May from imported resin. Import substitution was implemented in certain chemicals like neo-ferrum flakes, iodine concentrate and paracetamol.

- 800 No. of equity share & 200 pref. shares issued by Feb. 1963. Around March 1963, 800 No. of equity shares issued at par to collaborators. Around Dec. 1964, 800 right equity shares issued at par in prop. 1:2 & pref. shares redeemed. In Sept. 1967, 1,200 No. of equity shares issued at par in prop. 1:2. In Sept. 1969, Rs 9 lakhs capitalised to make partly paid shares fully paid-up.

1971 - The name of Comp. was changed to Duphar-Interfran Ltd.

1975 - The second phase was [irradiations] of vitamin `D' was implemented. The Company products included `Crookes' transfusion, crocin & lacto-calamine, Duphar research specialities of vasodilators & progrestational agents.

- In Dec. 1970, shares subdivided. In Oct. 1975, 36,000 bonus shares issued in prop. 1:1.

1977 - On 24-12-1976, shares subdivided. During July 1977, 2,00,000 shares offered [prem. Rs 2.50 per shares] to the public.

1979 - The Comp. undertook to set up a joint venture Comp. under the name Fermentapharma Biodil Ltd., at Takoli village, Mandi district in Himachal Pradesh for manufacture of basic drug intermediates used in the production of essential semi-synthetic antibiotics.

1984 - A modernisation & replacement to programme was taken up at the cost of Rs 100 lakhs.

- 4,60,000 bonus equity shares issued in prop. 1:2.

1985 - Profitability was affected by a strike in the Vapi unit. The Vapi factory couldn't make adequate contribution to sales on Acc. of low employee effectiveness.

- The Comp. obtained registration for manufacture of some bulk drugs & their formulations.

1988 - The Comp. privately placed with financial institutions 1,20,000-14% non-convertible debentures of Rs 100 each for Rs 120 lakhs.

- 4,60,000 bonus shares issued in prop. 1:3.

1991 - 3,22,000 shares issued [prem. Rs 35 per shares], 3.06,667 shares rights [prop. 1:6s] & 15,333 shares to employees [all were taken ups]. Allotment was made on 1.6.1991.

1992 - The Comp. continued to concentrate towards development of new formulation, bulk drugs & intermediates in the field of synthetic & fermentation technology & in improving process of existing formulation & bulk drugs.

- The Comp. proposed to set up a third manufacturing unit at Takwe, Maharashtra for commercial production of formulation. The Comp. proposed to introduce Vitamin D3 combination for veterinary use.

- The Comp. has developed chemical preparation of Sulbactam, a beta-lactamase inhibitor. Amoxycillin Dispersible Tablet was introduced in the market.

- During the year the company Pilot Plant was engaged in the scaling up of in-house processes developed by company R and D Division for manufacture of 7-ADCA by enzymatic conversion of Ceph-G, jCephalexin & Sulbactam. Besides , locally developed technology for Cholorzoxazone was tried out in the Pilot Plant.

- It is proposed to install Heat Recovery System & a high efficiency boiler at the Vapi Works.

1993 - The Comp. has undertaken expansion programme by recreating its Vitamin D3 plant at Thane.

- Vitamin D3 preparation in Arachis Oil for Animal Feed was developed. The Comp. proposes to introduce Vitamin D3 combination for veterinary use.

- During the year the company Pilot Plant was engaged in the scaling up of in-house processes for Sulbactam & Chlorzoxazone.

1994 - The Company, proposed to issue 3,60,333 New Equity Shares of Rs. 10/- each as Rights Shares at a premium of Rs.45 per share. These shares will be offered to the Shareholders of Comp. in the ratio of one such New Equity Share for every six existing shares held.

- Two new bulk drugs namely Chlorzoxazone & Sulbactam Sodium which were developed through indigenously developed in-house technology have been successfully manufactured on commercial scale essentially for captive consumption.

- Vitamin D3, liquid formulation for Animal Feed has been developed & is being launched in the market.

1995 - The Comp. offered 3,60,333 No. of equity shares of Rs 10 each at a premium of Rs 45 per share on rights basis to the existing shareholders in the ratio of 1:6. The number of shares offered was increased to 3,62,871 on Acc. of rounding off of fractional entitlement. All were taken up.

- The Comp. set up a third manufacturing unit at village Takwe [Budruks], Taluka - Maval, District - Pune.

1996 - The Comp. effected sale of its main product namely, 'Crocin range' during the year since it was not giving the expected growth & yield & its contribution to profit was at a decreasing rate.

- The Comp. has already launched in February one of Gynaec products under the brand name 'Yutopar'. The other new products in the pipeline are Luvox, a psychotropic product.

- The Comp. introduced Voluntary Retirement Scheme for its workmen & staff members at Thane Factory & Head Office.

1997 - During the year, the Comp. launched a new product under the brand name UDILIV for chronic hepatitis, cholestasis and dissolution of gall stones indications.

- The Comp. has an R and D Laboratory approved by DSIR for chemicals & pharmaceutical research & development activity.

- A wage settlement was signed with Unions of Medical Representatives. Similarly, a wage agreement with the Union of Thane & H.O. Workmen & Staff was also signed.

1998 - Duphar-Interfran is present in categories like antibiotics, anti-stress therapy, iodine therapy & muscle spasm. Some of its well-known brands include Moxydil, Ginsec & Duodil tablets.

- Duphar is also planning to launch new formulations in various categories.

- The company R&D laboratory is now trying to develop and market new animal-feed supplement containing vitamins and minerals.

- Duphar-Interfran also plans to launch formulations in various categories. The Comp. launched a product under the brand name Udiliv for chronic hepatitis, cholestasis & dissolution of gall stones indications.

1999 - The Comp. has DSIR approved R&D Centre. During the year, research programme for finding out new lead molecules of medicinal importance & development of indigenous technologies for major drugs & intermediates were continued.

- Electrical capacitors of sufficient size were installed at main electrical distribution & at key motor control panels by which the power factor was maintained at the efficient level resulting in considerable power saving.

- The Comp. has an extensive computer network.

2000 - Duphar-Interfran Ltd [DILs] has said it is demerging its pharmaceutical business into a new company.

- The Comp. has signed agreements with NSDL & CDSL for dematerialisation of company shares & for electronic connectivity.

2002-Duphar-Interfran Ltd has informed that Mr Kunal Kashyap has been appointed as a Director on the Board of company.

2007

- Dil Ltd has appointed Mr. Sanjay Buch as an additional director [Independent Categorys] with effect from April 28, 2007.